Prostate Cell News Volume 5.21 | Jun 13 2014

    0
    14
    Prostate Cell News 5.21 June 13, 2014

    Prostate Cell News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  Prostate Cell News on Twitter

     
    TOP STORY
    MicroRNA-128 Suppresses Prostate Cancer by Inhibiting BMI-1 to Inhibit Tumor-Initiating Cells
    Researchers showed that exogenously introduced microRNA-128 suppresses tumor regeneration in multiple prostate cancer xenograft models. Cancer stem-like cell associated properties were blocked, including holoclone and sphere formation as well as clonogenic survival. [Cancer Res] Abstract
    New TeSR™-E8™ is Here For Feeder-Free Culture of Human ES Cells and iPS Cells

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    LABORATORY RESEARCH

    ID4 Inactivation Promotes De Novo Steroidogenesis and Castration Resistant Prostate Cancer
    Researchers investigated the effect of loss of Inhibitor of differentiation 4 (ID4) in prostate cancer cell lines on tumorigenicity and addresses the underlying mechanism. [Mol Endocrinol] Abstract

    A Novel Small Molecule Hybrid of Vorinostat and DACA Displays Anticancer Activity against Human Hormone-Refractory Metastatic Prostate Cancer through Dual Inhibition of Histone Deacetylase and Topoisomerase I
    WJ35435, a new hybrid of vorinostat and DACA potently inhibited histone deacetylase activity in kinase assay and cell-based examination. WJ35435 showed better potency than vorinostat and DACA against PC-3 and DU-145, two human hormone-refractory metastatic prostate cancer cell lines, but not benign prostate cells. [Biochem Pharmacol] Abstract

    miR-124 Exhibits Antiproliferative and Antiaggressive Effects on Prostate Cancer Cells through PACE4 Pathway
    Scientists strived to find some key microRNAs to decrease malignancy and invasiveness of prostate cancer cells through regulating PACE4 expression. [Prostate] Full Article

    Generation and Characterization of a Canine EGFP-HMGA2 Prostate Cancer In Vitro Model
    Investigators established a canine CT1258-EGFP-HMGA2 prostate cancer cell line stably overexpressing High-Mobility-Group Protein A2 (HMGA2) linked to EGFP and in addition the reference cell line CT1258-EGFP expressing solely EGFP to exclude EGFP-induced effects. [PLoS One] Full Article

    Transcription Factors Involved in Prostate Gland Adaptation to Androgen Deprivation
    Researchers identified transcription factors that regulate gene expression after androgen deprivation by castration. [PLoS One] Full Article

    Zeb1 Promotes Androgen Independence of Prostate Cancer via Induction of Stem Cell-Like Properties In Vitro Model
    Investigators demonstrated elevated expression of Zeb1 in androgen-independent prostate cancer cells and prostate tumors of castrated PTEN conditional knockout mice. [Exp Biol Med] Abstract

    CLINICAL RESEARCH

    5α-Reductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer
    Researchers aimed to determine the association between 5α-reductase inhibitors use and development of high-grade or lethal prostate cancer. [JAMA Intern Med] Abstract

    A Three-Protein Biomarker Panel Assessed in Diagnostic Tissue Predicts Death from Prostate Cancer for Men with Localized Disease
    Scientists evaluated whether a panel of biomarkers, associated with a range of disease outcomes in previous studies, could predict death from prostate cancer for men with localized disease. [Cancer Med] Full Article

    A Functional Variant in NKX3.1 Associated with Prostate Cancer Risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    Results indicated that variation in NKX3.1 expression combined with selenium or vitamin E treatment modified the risk of prostate cancer. Genetic background may modulate the effects of antioxidant supplementation thought to act as chemoprevention agents. [Cancer Prev Res] Abstract

    Heading to ISSCR 2014 in Vancouver?
    Come Visit Connexon Creative at Booth #507 and Enter to Win $100 Amazon Gift Card!

    Listen Now: Podcast on ALDH in Breast Cancer Treatment Response

     
    REVIEWS
    Androgen Receptor: Structure, Role in Prostate Cancer and Drug Discovery
    Researchers present an overview of androgen receptor structure and activity, its actions in prostate cancer, and how structural information and high-throughput screening have been or can be used for drug discovery. [Acta Pharmacol Sin] Full Article

    Visit our reviews page to see a complete list of reviews in the prostate cell research field.

     
    INDUSTRY NEWS
    Isis Pharmaceuticals Earns $15 Million from AstraZeneca for Initiation of Phase I Study of ISIS-AR Rx
    Isis Pharmaceuticals, Inc. announced that AstraZeneca has initiated a Phase I clinical study of ISIS-ARRx in patients with cancer. ISIS-ARRx is an antisense drug designed to treat patients with prostate cancer by inhibiting the production of the androgen receptor. [Isis Pharmaceuticals, Inc.] Press Release

    George Washington Cancer Institute Contributes to Clinical Care Guidelines for the Growing Number of Prostate Cancer Survivors
    In response to the increasing need to support primary care clinicians who care for prostate cancer survivors, the American Cancer Society (ACS), with support from the George Washington Cancer Institute and a panel of experts, has published the ACS Prostate Cancer Survivorship Care Guidelines. [George Washington University] Press Release

    From our sponsor:
    Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW 2014 Best of American Society of Clinical Oncology (ASCO) Chicago Meeting
    August 15 – 16, 2014
    Chicago, United States

    Visit our events page to see a complete list of events in the prostate cell community.

     
    JOB OPPORTUNITIES
    NEW Postdoctoral Position – Prostate Cancer Aggressiveness and Progression in Prostate Cancer (Roswell Park Cancer Institute)

    PhD Studentship – Prostate Cancer Research (Cardiff University)

    Postdoctoral Fellow – Prostate Cancer Research (Henry Ford Hospital)

    Research Fellow – Molecular Mechanisms of Prostate Cancer (Northwestern University- Feinberg School of Medicine)

    Research Coordinator / Research Assistant – Oncology (NYU Langone Medical Center Department of Pathology)

    Postdoctoral Research Associate – Prostate Cancer Research (Medical University of South Carolina)

    Postdoctoral Fellow – Translational Prostate Cancer (Cleveland Clinic)

    Postdoctoral Researcher – Therapeutic Targets for Cancer Treatment (Sanford Burnham Medical Research Institute)

    Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

    Research Associate – Cell Separation (STEMCELL Technologies Inc.)

    Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

    Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)


    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Prostate Cell News? Click here to submit!

    Comments or Suggestions? Submit your feedback here.

    Learn more about Prostate Cell News: Archives | Events | Contact Us